Literature DB >> 646339

Reversible inhibition of cellular metabolism by ribavirin.

A Larsson, K Stenberg, B Oberg.   

Abstract

The broad spectrum antiviral drug ribavirin (Virazole, 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide) inhibits cellular macromolecular synthesis as well as cell division in eucaryotic cells. The concentration and time dependence have been studied. One-hour treatment with 25 muM ribavirin or 18 h with 2 muM inhibited the deoxyribonucleic acid synthesis to 50%. Higher concentrations of ribavirin were required to obtain a similar inhibition of ribonucleic acid and protein synthesis. This effect on cell metabolism and cell division can be reversed by removing the drug from the cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 646339      PMCID: PMC352205          DOI: 10.1128/AAC.13.2.154

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  The selective inhibition of viral DNA synthesis by chemotherapeutic agents: an indicator of clinical usefulness?

Authors:  J C Drach; C Shipman
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

2.  Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent.

Authors:  W E Müller; A Maidhof; H Taschner; R K Zahn
Journal:  Biochem Pharmacol       Date:  1977-06-01       Impact factor: 5.858

3.  The relationship between the metabolism of ribavirin and its proposed mechanism of action.

Authors:  J P Miller; L J Kigwana; D G Streeter; R K Robins; L N Simon; J Roboz
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

4.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

5.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

  5 in total
  10 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

2.  Inhibitory effect of a nucleotide analog on infectious salmon anemia virus infection.

Authors:  Andrea Rivas-Aravena; Eva Vallejos-Vidal; Marcelo Cortez-San Martin; Felipe Reyes-Lopez; Mario Tello; Patricia Mora; Ana María Sandino; Eugenio Spencer
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

Review 3.  Ribavirin: a clinical overview.

Authors:  H Fernandez; G Banks; R Smith
Journal:  Eur J Epidemiol       Date:  1986-03       Impact factor: 8.082

4.  Effect of ribavirin on macromolecular synthesis in vesicular stomatitis virus-infected cells.

Authors:  P Toltzis; A S Huang
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

5.  Reversible effects on cellular metabolism and proliferation by trisodium phosphonoformate.

Authors:  K Stenberg; A Larsson
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

6.  Enhancement of activity against influenza viruses by combinations of antiviral agents.

Authors:  F G Hayden; R G Douglas; R Simons
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

7.  Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription.

Authors:  P Toltzis; K O'Connell; J L Patterson
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Inhibition of lymphocyte proliferative responses by ribavirin.

Authors:  D L Peavy; W C Koff; D S Hyman; V Knight
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

9.  Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.

Authors:  J J Kirsi; P A McKernan; N J Burns; J A North; B K Murray; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 10.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.